Transition of a Home Hemodialysis Program to the Tablo System

David E. Henner, DO



BACKGROUND

Home hemodialysis (HHD) has many reported benefits; however, device and treatment frequency options have been limited. Berkshire Medical Center transitioned its existing HHD program to Tablo.

Tablo is an easy-to-learn system approved for home use capable of achieving clearance goals in as little as three treatments per week. Tablo features integrated water purification, on demand dialysate production and two-way wireless data transmission.

OBJECTIVE

Report on the successful conversion of the Berkshire Medical Center's HHD program to the Tablo System.

METHODS

Existing and new HHD patients were trained on Tablo by facility nursing staff. Information regarding patient demographics, treatment frequency, training time and patient satisfaction were documented. Tablo prescriptions and treatment results were obtained and recorded remotely.

RESULTS

From July to October 2020, four patients between the ages of 36 to 54 were trained for home hemodialysis on Tablo. Three patients had prior HHD experience and all were prescribed a dialysis frequency of 5x/week. One patient was new to home. Standard facility training time prior to Tablo was 4-6 weeks. For all patients, Tablo training was completed in two weeks with an average of training time of 38 hours.

Treatment frequency was 3.7 treatments per week. All patients achieved target standard weekly Kt/V of \ge 2.0. Treatment adherence during the observation period was 100% (68/68), with a treatment success rate of 98.5%.

Tablo can be used by a wide variety of demographics (age, prior HHD, new to dialysis). Patients and nurses reported high satisfaction with training and rated Tablo easier to use than prior technology.

CONCLUSION

Conversion of an HHD program to Tablo can allow shortened training time, the ability to decrease treatment frequency while achieving adequate clearance, and result in favorable patient and nurse experience.

Tablo is easy to use and takes less time than prior HHD devices (NxStage)



On Tablo, all patients successfully achieved clearance goals (Kt/V of ≥ 2.0) in fewer avg. weekly treatments





